Home » Stocks » BVS

Bioventus, Inc. (BVS)

Stock Price: $18.42 USD 0.79 (4.48%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $18.50 +0.08 (0.43%) Jun 11, 4:00 PM
Market Cap 1.05B
Revenue (ttm) 324.29M
Net Income (ttm) n/a
Shares Out 41.80M
EPS (ttm) n/a
PE Ratio n/a
Forward PE 12.17
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $18.42
Previous Close $17.63
Change ($) 0.79
Change (%) 4.48%
Day's Open 18.00
Day's Range 17.67 - 18.60
Day's Volume 226,216
52-Week Range 10.74 - 19.51

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

As of late, it has definitely been a great time to be an investor of Bioventus (BVS).

2 weeks ago - Zacks Investment Research

DURHAM, N.C., May 17, 2021 (GLOBE NEWSWIRE) -- Senior management of Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, will present at the Ca...

3 weeks ago - GlobeNewsWire

DURHAM, N.C., May 12, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for three ...

1 month ago - GlobeNewsWire

Fourteen Facilities Across the US Receive Multidisciplinary Therapy Solution Fourteen Facilities Across the US Receive Multidisciplinary Therapy Solution

1 month ago - GlobeNewsWire

DURHAM, N.C., April 12, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that first quarter of fis...

2 months ago - GlobeNewsWire

DURHAM, N.C., March 30, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has acquired Bioness, Inc. (“Bioness”), a...

2 months ago - GlobeNewsWire

DURHAM, N.C., March 25, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the ...

2 months ago - GlobeNewsWire

DURHAM, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a leader in solutions for innovative healing, reported that the first patients have been enr...

3 months ago - GlobeNewsWire

DURHAM, N.C., March 04, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has appointed Larry Chen as Managing Dire...

3 months ago - GlobeNewsWire

DURHAM, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that fourth quarter and f...

3 months ago - GlobeNewsWire

Bioventus Inc. ("Bioventus" or the “Company”) today announced the pricing of its initial public offering...

4 months ago - GlobeNewswire

DURHAM, N.C.--Bioventus Inc. ("Bioventus" or the “Company”), today announced that it has commenced the initial public offering of its Class A common stock. Bioventus is offering 7,350,000 shares of its ...

4 months ago - Business Wire

RESEARCH TRIANGLE PARK - Biotech companies continue to jump in line to join the public markets. Bioventus, a medical device maker whose portfolio includes...

4 months ago - WRAL TechWire

This is the second time North Carolina medical device maker applied to go public via an initial public offering. In 2016, the company rescinded its application citing market conditions.

4 months ago - News Observer

Bioventus, which offers orthobiologics products for musculoskeletal conditions, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. The company had previously file...

4 months ago - NASDAQ

Bioventus, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC

About BVS

Bioventus is a global medical device company focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body’s natural healing process. We believe our non-invasive medical device and biologic products play a critical role in supporting the body’s own healing mechanisms to heal or eliminate the pain caused by orthopedic conditions and problems, which we define as our active healing products. These products address an estimated $6.0 billion market opportuni... [Read more...]

Industry
Diagnostics & Research
IPO Date
Feb 11, 2021
CEO
Kenneth M. Reali
Employees
900
Stock Exchange
NASDAQ
Ticker Symbol
BVS
Full Company Profile

Financial Performance

In 2020, Bioventus's revenue was $321.16 million, a decrease of -5.58% compared to the previous year's $340.14 million. Earnings were $16.41 million, an increase of 139.54%.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Bioventus is 20.67, which is an increase of 12.21% from the latest price.

Price Target
$20.67
(12.21% upside)